Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 28.64 points (-0.2%) at 16,839 as of Thursday, June 26, 2014, 3:55 PM ET. The NYSE advances/declines ratio sits at 1,444 issues advancing vs. 1,544 declining with 166 unchanged.

The Health Services industry as a whole closed the day down 0.2% versus the S&P 500, which was down 0.1%. Top gainers within the Health Services industry included Allied Healthcare Products ( AHPI), up 4.6%, Pro-Dex ( PDEX), up 8.0%, SunLink Health Systems ( SSY), up 5.8%, Akers Biosciences ( AKER), up 2.3% and BioLife Solutions ( BLFS), up 3.0%.

TheStreet Ratings Group would like to highlight 3 stocks pushing the industry higher today:

BioLife Solutions ( BLFS) is one of the companies that pushed the Health Services industry higher today. BioLife Solutions was up $0.06 (3.0%) to $2.03 on light volume. Throughout the day, 5,443 shares of BioLife Solutions exchanged hands as compared to its average daily volume of 77,100 shares. The stock ranged in a price between $1.97-$2.04 after having opened the day at $1.97 as compared to the previous trading day's close of $1.97.

BioLife Solutions, Inc. develops, manufactures, and markets patented hypothermic storage and cryopreservation solutions for cells and tissues. BioLife Solutions has a market cap of $24.3 million and is part of the health care sector. Shares are unchanged year-to-date as of the close of trading on Wednesday. Currently there is 1 analyst who rates BioLife Solutions a buy, no analysts rate it a sell, and none rate it a hold.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings rates BioLife Solutions as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income and weak operating cash flow.

Highlights from TheStreet Ratings analysis on BLFS go as follows:

  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Health Care Equipment & Supplies industry. The net income has significantly decreased by 7885.7% when compared to the same quarter one year ago, falling from -$0.01 million to -$0.56 million.
  • Net operating cash flow has significantly decreased to -$0.89 million or 609.52% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.
  • This stock's share value has moved by only 51.99% over the past year. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
  • BIOLIFE SOLUTIONS INC's earnings have gone downhill when comparing its most recently reported quarter with the same quarter a year earlier. This company has not demonstrated a clear trend in earnings over the past 2 years, making it difficult to accurately predict earnings for the coming year. During the past fiscal year, BIOLIFE SOLUTIONS INC continued to lose money by earning -$0.14 versus -$0.42 in the prior year.
  • BLFS, with its decline in revenue, slightly underperformed the industry average of 3.6%. Since the same quarter one year prior, revenues slightly dropped by 4.4%. The declining revenue appears to have seeped down to the company's bottom line, decreasing earnings per share.

You can view the full analysis from the report here: BioLife Solutions Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

At the close, Akers Biosciences ( AKER) was up $0.10 (2.3%) to $4.24 on heavy volume. Throughout the day, 35,585 shares of Akers Biosciences exchanged hands as compared to its average daily volume of 18,900 shares. The stock ranged in a price between $3.74-$4.25 after having opened the day at $4.14 as compared to the previous trading day's close of $4.15.

Akers Biosciences has a market cap of $19.3 million and is part of the health care sector. Shares are down 38.8% year-to-date as of the close of trading on Wednesday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Highlights from TheStreet Ratings analysis on AKER go as follows:

You can view the full analysis from the report here: Akers Biosciences Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Allied Healthcare Products ( AHPI) was another company that pushed the Health Services industry higher today. Allied Healthcare Products was up $0.11 (4.6%) to $2.48 on heavy volume. Throughout the day, 13,874 shares of Allied Healthcare Products exchanged hands as compared to its average daily volume of 4,200 shares. The stock ranged in a price between $2.27-$2.48 after having opened the day at $2.27 as compared to the previous trading day's close of $2.37.

Allied Healthcare Products, Inc. manufactures, markets, and distributes respiratory care products, medical gas equipment, and emergency medical products in Canada, Mexico, Central and South America, Europe, the Middle East, and the Far East. Allied Healthcare Products has a market cap of $18.9 million and is part of the health care sector. Shares are up 4.0% year-to-date as of the close of trading on Wednesday. Currently there are no analysts who rate Allied Healthcare Products a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Allied Healthcare Products as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, poor profit margins and generally disappointing historical performance in the stock itself.

Highlights from TheStreet Ratings analysis on AHPI go as follows:

  • ALLIED HEALTHCARE PRODS INC has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. The company has reported a trend of declining earnings per share over the past two years. During the past fiscal year, ALLIED HEALTHCARE PRODS INC reported poor results of -$0.15 versus -$0.06 in the prior year.
  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Health Care Equipment & Supplies industry. The net income has significantly decreased by 247.3% when compared to the same quarter one year ago, falling from -$0.28 million to -$0.97 million.
  • Current return on equity is lower than its ROE from the same quarter one year prior. This is a clear sign of weakness within the company. Compared to other companies in the Health Care Equipment & Supplies industry and the overall market, ALLIED HEALTHCARE PRODS INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • The gross profit margin for ALLIED HEALTHCARE PRODS INC is rather low; currently it is at 22.80%. Regardless of AHPI's low profit margin, it has managed to increase from the same period last year. Despite the mixed results of the gross profit margin, AHPI's net profit margin of -10.63% significantly underperformed when compared to the industry average.
  • The share price of ALLIED HEALTHCARE PRODS INC has not done very well: it is down 5.16% and has underperformed the S&P 500, in part reflecting the company's sharply declining earnings per share when compared to the year-earlier quarter. The fact that the stock is now selling for less than others in its industry in relation to its current earnings is not reason enough to justify a buy rating at this time.

You can view the full analysis from the report here: Allied Healthcare Products Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.